Page 152 - 南京医科大学学报自然科学版
P. 152

第42卷第1期
               ·146 ·                            南 京    医 科 大 学 学         报                        2022年1月


             [19] JACOT W,COTTU P,BERGER F,et al. Actionability of   search project of a prospective randomized phase Ⅲ trial
                   HER2⁃amplified circulating tumor cells in HER2⁃nega⁃  [J]. PLoS One,2017,12(6):e0173593
                   tive metastatic breast cancer:the Circe T⁃DM1 trial[J].  [23] WALLWIENER M,HARTKOPF A D,RIETHDORF S,et
                   Breast Cancer Res,2019,21(1):121                  al. The impact of HER2 phenotype of circulating tumor
             [20] DEUTSCH T M,RIETHDORF S,FREMD C,et al. HER2⁃       cells in metastatic breast cancer:a retrospective study in
                   targeted therapy influences CTC status in metastatic  107 patients[J]. BMC Cancer,2015,15:403
                   breast cancer[J]. Breast Cancer Res Treat,2020,182  [24] GANCBERG D,DI LEO A,CARDOSO F,et al. Compari⁃
                  (1):127-136                                        son of HER⁃2 status between primary breast cancer and
             [21] BIDARD F C,FEHM T,IGNATIADIS M,et al. Clinical     corresponding distant metastatic sites[J]. Ann Oncol,
                   application of circulating tumor cells in breast cancer:  2002,13(7):1036-1043
                   overview of the current interventional trials[J]. Cancer  [25] JORDAN N V,BARDIA A,WITTNER B S,et al. HER2
                   Metastasis Rev,2013,32(1/2):179-188               expression identifies dynamic functional states within cir⁃
             [22] JAEGER B S,NEUGEBAUER J,ANDERGASSEN U,et           culating breast cancer cells[J]. Nature,2016,537
                   al. The HER2 phenotype of circulating tumor cells in  (7618):102-106
                   HER2 ⁃ positive early breast cancer:a translational re⁃                [收稿日期] 2020-03-02
                                                                                               (本文编辑:蒋 莉)




              


             (上接第120页)
                                                                     及耐药性分析[J]. 临床和实验医学杂志,2015,14(6):
                   level modelling analysis[J]. Lancet Infect Dis,2019,19  512-515
                  (1):56-66                                     [17] 朱英娟,王春媛,顾国忠,等. 血流感染的病原学分布和
             [14] 吴   旻,陈   琼,许湘飞,等. 碳青霉烯类耐药高黏液型                     危险因素及抗菌药敏感性分析[J]. 当代医学,2020,26
                   肺炎克雷伯菌分子流行病学和患者临床特征研究[J].                        (35):175-177
                   实用预防医学,2020,27(12):1525-1528                 [18] 马曦立,刘     霞,吴   鑫,等. 慢性肾功能衰竭血液透析
              [15] DURDU B,HAKYEMEZ I N,BOLUKCU S,et al. Mortality   导管相关性血流感染病原菌耐药性及其影响因素[J].
                   markers in nosocomial Klebsiella pneumoniae blood⁃  中华医院感染学杂志,2021,31(3):385-389
                   stream infection[J]. Springerplus,2016,5(1):1892                       [收稿日期] 2021-02-04
             [16] 陈   娜,苏建荣. 血培养阳性混合菌感染的病原菌分布                                                  (本文编辑:蒋      莉)
   147   148   149   150   151   152   153   154   155   156   157